Raymond James Maintains Outperform on Solaris Energy Infr, Raises Price Target to $96
Raymond James analyst J.R. Weston maintains Solaris Energy Infr (NYSE:SEI) with a Outperform and raises the price target from $82 to $96.
News
Source-attributed headlines with timestamps and links to the companies and crypto markets they mention.
Latest Coverage
30 headlines
Raymond James analyst J.R. Weston maintains Solaris Energy Infr (NYSE:SEI) with a Outperform and raises the price target from $82 to $96.
UBS analyst Doug Schenkel maintains Natera (NASDAQ:NTRA) with a Buy and raises the price target from $290 to $435.
Needham analyst Ryan MacDonald reiterates Barnes & Noble Education (NYSE:BNED) with a Buy and maintains $16 price target.
Raymond James analyst John Freeman maintains Expand Energy (NASDAQ:EXE) with a Strong Buy and raises the price target from $145 to $147.
BTIG analyst Gray Powell reiterates SailPoint (NASDAQ:SAIL) with a Buy and maintains $21 price target.
UBS analyst Dan Brennan maintains Maravai LifeSciences (NASDAQ:MRVI) with a Neutral and raises the price target from $2.5 to $8.
Filed: 2026-09-09 AccNo: 0001325814-26-000142 Size: 184 KB Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 9.01: Financial Statements and Exhibits
https://www.apple.com/apple-events/event-stream/
Raymond James analyst Brian Peterson maintains Braze (NASDAQ:BRZE) with a Outperform and raises the price target from $27 to $33.
UBS analyst Dan Leonard maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $175 to $225.
HC Wainwright & Co. analyst Matthew Caufield reiterates Opus Genetics (NASDAQ:IRD) with a Buy and maintains $8 price target.
Raymond James analyst Sean McCutcheon maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and lowers the price target from $24 to $22.
Robinhood CEO Vlad Tenev defends 1:1 backed stock tokenization as Needham analysts signal a crypto bottom and long-term growth potential for HOOD.
Cipher Digital (CIFR) drops 8% to $16.99 amid market drag. Key technical levels: $16 support and $18 resistance.
Pyxis Oncology shared Phase 1 trial data for MICVO in head and neck cancer, showing a 36% response rate alongside analyst safety concerns.
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often